{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:49:46Z","timestamp":1788446986291,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.tmrv.2023.150754","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T11:26:43Z","timestamp":1692703603000},"page":"150754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["HIV Pre-Exposure Prophylaxis, Blood Donor Deferral, Occult Infection, and Risk of HIV Transmission by Transfusion: A Fine Balance Between Evidence-Based Donor Selection Criteria and Transfusion Safety"],"prefix":"10.1016","volume":"37","author":[{"given":"Jean-Fran\u00e7ois","family":"Leblanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Custer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thijs","family":"Van de Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Drews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2023.150754_bib0001","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/QAD.0000000000000268","article-title":"Prevention of HIV-1 transmission with postexposure prophylaxis after inadvertent infected blood transfusion","volume":"28","author":"Al-Hajjar","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.tmrv.2023.150754_bib0002","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/1570162X18666200804151118","article-title":"Clinical outcomes of post-exposure prophylaxis following occupational exposure to human immunodeficiency virus at Dental Departments of Hiroshima University Hospital","volume":"18","author":"Shintani","year":"2020","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.tmrv.2023.150754_bib0003","doi-asserted-by":"crossref","first-page":"E1448","DOI":"10.1503\/cmaj.170494","article-title":"Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis","volume":"189","author":"Tan","year":"2017","journal-title":"CMAJ"},{"key":"10.1016\/j.tmrv.2023.150754_bib0004","unstructured":"Tan D. HIV pre- and post-exposure prevention measures: clinical practice guideline. CMAJ Podcasts, https:\/\/soundcloud.com\/cmajpodcasts\/170494-guide (transcript available at https:\/\/www.cmaj.ca\/transcript-170494); 2017 [accessed September 18, 2023]."},{"key":"10.1016\/j.tmrv.2023.150754_bib0005","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1097\/QAD.0000000000003494","article-title":"Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition","volume":"37","author":"Fonner","year":"2023","journal-title":"AIDS"},{"key":"10.1016\/j.tmrv.2023.150754_bib0006","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV infection: epidemiology, pathogenesis, treatment, and prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2023.150754_bib0007","series-title":"The future of HIV-1 therapeutics: Resistance is futile?","year":"2015"},{"key":"10.1016\/j.tmrv.2023.150754_bib0008","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","article-title":"Prevention, treatment and cure of HIV infection","volume":"21","author":"Landovitz","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.tmrv.2023.150754_bib0009","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1089\/aid.2018.0118","article-title":"Barriers for HIV cure: the latent reservoir","volume":"34","author":"Castro-Gonzalez","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.tmrv.2023.150754_bib0010","article-title":"The reservoir of latent HIV","volume":"12","author":"Chen","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.tmrv.2023.150754_bib0011","unstructured":"Gilead Sciences, Inc. Truvada\u00ae Package Insert, p. 1-38, https:\/\/www.gilead.com\/\u223c\/media\/files\/pdfs\/medicines\/hiv\/truvada\/truvada_pi.pdf; 2020 [accessed September 18, 2023]."},{"key":"10.1016\/j.tmrv.2023.150754_bib0012","unstructured":"Gilead Sciences, Inc. Descovy\u00ae Package Insert, p. 1-43, https:\/\/www.gilead.com\/-\/media\/55b14ac03ef94b6f98d5d3c31ea0137b.ashx; 2022 [accessed September 18, 2023]."},{"key":"10.1016\/j.tmrv.2023.150754_bib0013","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and latest advances in antiretroviral therapy","volume":"43","author":"Men\u00e9ndez-Arias","year":"2022","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.tmrv.2023.150754_bib0014","first-page":"399","article-title":"Challenges and opportunities for preexposure prophylaxis","volume":"29","author":"Cambou","year":"2021","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.tmrv.2023.150754_bib0015","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/S2352-3018(19)30341-8","article-title":"On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial","volume":"7","author":"Antoni","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tmrv.2023.150754_bib0016","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1016\/S2352-3018(22)00133-3","article-title":"Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study","volume":"9","author":"Molina","year":"2022","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tmrv.2023.150754_bib0017","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11904-019-00450-9","article-title":"Current and future PrEP medications and modalities: on-demand, injectables, and topicals","volume":"16","author":"Beymer","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.tmrv.2023.150754_bib0018","unstructured":"ViiV Healthcare. Apretude Package Insert, p. 1-48, https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Apretude\/pdf\/APRETUDE-PI-PIL-IFU.PDF; 2023 [accessed September 18, 2023]."},{"key":"10.1016\/j.tmrv.2023.150754_bib0019","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13584-017-0139-2","article-title":"An end to lifetime blood donation ban in Israel for MSM would be a major step toward a science-based policy that reduces stigma","volume":"6","author":"Cahill","year":"2017","journal-title":"Isr J Health Policy Res"},{"key":"10.1016\/j.tmrv.2023.150754_bib0020","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1097\/QAD.0000000000003644","article-title":"Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis","volume":"37","author":"Hazra","year":"2023","journal-title":"AIDS"},{"key":"10.1016\/j.tmrv.2023.150754_bib0021","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/vox.12516","article-title":"Blood safety implications of donors using HIV pre-exposure prophylaxis","volume":"112","author":"Seed","year":"2017","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2023.150754_bib0022","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/tme.12957","article-title":"Motivations for blood donation by HIV-positive individuals on antiretrovirals in South Africa: a qualitative study","volume":"33","author":"van den Berg","year":"2023","journal-title":"Transfus Med"},{"key":"10.1016\/j.tmrv.2023.150754_bib0023","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/v14071426","article-title":"The impact of early antiretroviral treatment (ART) for HIV on the sensitivity of the latest generation of blood screening and point of care assays","volume":"14","author":"Vermeulen","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.tmrv.2023.150754_bib0024","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150937","article-title":"Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection","volume":"132","author":"Mitchell","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tmrv.2023.150754_bib0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/QAD.0000000000001343","article-title":"Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251","volume":"31","author":"Andrews","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.tmrv.2023.150754_bib0026","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2020006890","article-title":"HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern","volume":"136","author":"Custer","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2023.150754_bib0027","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/vox.13011","article-title":"Effect of HIV pre-exposure prophylaxis (PrEP) on detection of early infection and its impact on the appropriate post-PrEP deferral period","volume":"116","author":"Seed","year":"2021","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2023.150754_bib0028","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1111\/trf.16349","article-title":"Evaluation of a pre-exposure prophylaxis (PrEP)\/post-exposure prophylaxis (PEP) deferral policy among blood donors","volume":"61","author":"Saeed","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150754_bib0029","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1111\/trf.16698","article-title":"Influence of unreported HIV prophylaxis on the kinetics of post-blood donation HIV seroconversion","volume":"61","author":"Nishiya","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2023.150754_bib0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/sextrans-2021-054981","article-title":"Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP\/PEP) among blood donors: a pilot study, England June 2018 to July 2019","volume":"98","author":"Harvala","year":"2022","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.tmrv.2023.150754_bib0031","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.11.2300135","article-title":"Undeclared pre-exposure or post-exposure prophylaxis (PrEP\/PEP) use among syphilis-positive blood donors, England, 2020 to 2021","volume":"28","author":"Maddox","year":"2023","journal-title":"Euro Surveill"},{"key":"10.1016\/j.tmrv.2023.150754_bib0032","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tmrv.2023.150754_bib0033","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2023.150754_bib0034","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2023.150754_bib0035","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/infdis\/jiab576","article-title":"Characterization of human immunodeficiency virus (HIV) infections in women who received injectable cabotegravir or tenofovir disoproxil fumarate\/emtricitabine for HIV prevention: HPTN 084","volume":"225","author":"Eshleman","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmrv.2023.150754_bib0036","unstructured":"Devine D, BenAvram D. AABB Association Bulletin #22-03: Updated Recommendations on Donor Deferral for Use of Antiretroviral Medications for HIV Prevention and Treatment Including Long-Acting Injectable PrEP and the Impact on Blood Safety, p. 1-12, https:\/\/www.aabb.org\/docs\/default-source\/default-document-library\/resources\/association-bulletins\/ab22-03.pdf; 2022 [accessed September 18, 2023]."},{"key":"10.1016\/j.tmrv.2023.150754_bib0037","unstructured":"Association for the Advancement of Blood & Biotherapies. Impact of Injectable PrEP on Donor Testing and Screening 2022."},{"key":"10.1016\/j.tmrv.2023.150754_bib0038","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2023.150754_bib0039","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(14)70937-5","article-title":"Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial","volume":"14","author":"Baeten","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tmrv.2023.150754_bib0040","unstructured":"US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States \u2013 2021 Update Clinical Practice Guideline. Centers for Disease Control and Prevention, US Department of Health & Human Services, Atlanta, GA, USA,p. 1\u2013108, https:\/\/www.cdc.gov\/hiv\/pdf\/risk\/prep\/cdc-hiv-prep-guidelines-2021. 2021 [accessed September 18, 2023]."},{"key":"10.1016\/j.tmrv.2023.150754_bib0041","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","article-title":"Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial","volume":"4","author":"Markowitz","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tmrv.2023.150754_bib0042","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/QAI.0000000000001665","article-title":"Positive or not, that is the question: HIV testing for individuals on pre-exposure prophylaxis","volume":"78","author":"Zucker","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.tmrv.2023.150754_bib0043","doi-asserted-by":"crossref","first-page":"e25419","DOI":"10.1002\/jia2.25419","article-title":"Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review","volume":"22","author":"Elliott","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.tmrv.2023.150754_bib0044","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/hiv.12989","article-title":"A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections","volume":"22","author":"To","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.tmrv.2023.150754_bib0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1089\/aid.2020.0137","article-title":"Altered antibody responses in persons infected with HIV-1 while using preexposure prophylaxis","volume":"37","author":"Parker","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.tmrv.2023.150754_bib0046","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/infdis\/jiab152","article-title":"Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083","volume":"224","author":"Marzinke","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmrv.2023.150754_bib0047","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/cid\/ciw365","article-title":"Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology","volume":"63","author":"de Souza","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmrv.2023.150754_bib0048","doi-asserted-by":"crossref","first-page":"ofac191","DOI":"10.1093\/ofid\/ofac191","article-title":"Navigating human immunodeficiency virus screening recommendations for people on pre-exposure prophylaxis and the need to update testing algorithms","volume":"9","author":"Meyerowitz","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.tmrv.2023.150754_bib0049","unstructured":"Center for Biologics Envaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services, Silver Spring, MD, USA. Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products. Guidance for Industry, https:\/\/www.fda.gov\/media\/164829\/download; 2023 p. 1-19. [accessed September 18, 2023]"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796323000445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796323000445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:51Z","timestamp":1760138451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796323000445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0887796323000445"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2023.150754","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV Pre-Exposure Prophylaxis, Blood Donor Deferral, Occult Infection, and Risk of HIV Transmission by Transfusion: A Fine Balance Between Evidence-Based Donor Selection Criteria and Transfusion Safety","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2023.150754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"150754"}}